Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Cyclerion Therapeutics, Beacon Biosignals announces strategic partnership » 19:23
07/08/21
07/08
19:23
07/08/21
19:23
CYCN

Cyclerion Therapeutics

$3.67 /

+0.03 (+0.82%)

Cyclerion Therapeutics,…

Cyclerion Therapeutics, Inc. and Beacon Biosignals announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion's investigational therapeutics for neurological diseases associated with cognitive impairment. "Beacon Biosignals is the leader in the identification of disease-relevant EEG neurological biomarkers. We believe that the application of this technology to our innovative pipeline may be quite powerful in guiding efficient drug development, and we look forward to a productive partnership focused on successfully advancing CY6463 for diseases associated with cognitive impairment," said Andy Busch Ph.D., Chief Scientific Officer of Cyclerion Therapeutics.

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.67 /

+0.03 (+0.82%)

CYCN Cyclerion Therapeutics
$3.67 /

+0.03 (+0.82%)

Hot Stocks
Cyclerion Therapeutics, Beacon Biosignals expand partnership » 16:35
07/08/21
07/08
16:35
07/08/21
16:35
CYCN

Cyclerion Therapeutics

$3.67 /

+0.03 (+0.82%)

Cyclerion Therapeutics…

Cyclerion Therapeutics and Beacon Biosignals announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion's investigational therapeutics for neurological diseases associated with cognitive impairment. Beacon Biosignals' EEG neurobiomarker platform is engineered to discover and scale new clinical paradigms for patients with neurological and psychiatric disease. Distinct EEG profiles are associated with neurodevelopmental status and various neurological diseases, and can be affected by neurologically active therapeutics. The platform rapidly characterizes these effects and guides dose selection in humans to help overcome the challenges of translating PK/PD models from preclinical animal studies. Beacon Biosignals and Cyclerion previously collaborated on the analysis of data from a Cyclerion clinical translational pharmacology study of CY6463 which demonstrated clear effects on EEG parameters associated with aging and disease. These data were recently presented at the annual meeting of the American Academy of Neurology. Incorporation of the Beacon Biosignals approach in ongoing and planned Cyclerion patient studies is expected to support the continued clinical development of CY6463, the Company's lead clinical program, as well as CY3018, a next-generation preclinical program. CY6463 is an oral central nervous system, or CNS-penetrant sGC stimulator that is being developed for neurological diseases associated with cognitive impairment. CY6463 was designed to address multiple pathophysiological features of neurodegenerative and neuropsychiatric diseases associated with cognitive impairment. Results from initial CY6463 clinical studies have demonstrated favorable safety and tolerability and pharmacologically relevant drug exposure in the cerebral spinal fluid. In addition, CY6463 resulted in promising impacts on EEG measures, neuroinflammation, and other neurophysiological measures that support continued clinical development.

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.67 /

+0.03 (+0.82%)

CYCN Cyclerion Therapeutics
$3.67 /

+0.03 (+0.82%)

Over a month ago
Syndicate
Cyclerion Therapeutics files to sell 5.74M shares of common stock for holders  16:50
06/16/21
06/16
16:50
06/16/21
16:50
CYCN

Cyclerion Therapeutics

$3.80 /

+ (+0.00%)

 
ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.80 /

+ (+0.00%)

CYCN Cyclerion Therapeutics
$3.80 /

+ (+0.00%)

On The Fly
Fly Intel: After-Hours Movers » 18:31
06/07/21
06/07
18:31
06/07/21
18:31
SFIX

Stitch Fix

$58.21 /

+2.74 (+4.94%)

, REVG

REV Group

$19.63 /

+0.345 (+1.79%)

, MRVL

Marvell

$48.30 /

-0.42 (-0.86%)

, CYCN

Cyclerion Therapeutics

$3.13 /

-0.06 (-1.88%)

, SLQT

SelectQuote

$19.55 /

-0.24 (-1.21%)

, CHS

Chico's

$5.75 /

+0.37 (+6.88%)

, COUP

Coupa Software

$236.34 /

+6.33 (+2.75%)

, HQY

HealthEquity

$82.31 /

+1.16 (+1.43%)

, PLBY

PLBY Group

$52.23 /

+6.38 (+13.91%)

, APR

Apria

$31.01 /

+0.235 (+0.76%)

, LESL

Leslie's

$31.22 /

+1.52 (+5.12%)

, MARA

Marathon Digital

$24.36 /

+0.03 (+0.12%)

, KDP

Keurig Dr Pepper

$36.85 /

-0.04 (-0.11%)

, RIOT

Riot Blockchain

$28.82 /

-0.33 (-1.13%)

, ETSY

Etsy

$168.33 /

+4.13 (+2.52%)

Check out this evening's…

ShowHide Related Items >><<
SLQT SelectQuote
$19.55 /

-0.24 (-1.21%)

SFIX Stitch Fix
$58.21 /

+2.74 (+4.94%)

RIOT Riot Blockchain
$28.82 /

-0.33 (-1.13%)

REVG REV Group
$19.63 /

+0.345 (+1.79%)

PLBY PLBY Group
$52.23 /

+6.38 (+13.91%)

MRVL Marvell
$48.30 /

-0.42 (-0.86%)

MARA Marathon Digital
$24.36 /

+0.03 (+0.12%)

LESL Leslie's
$31.22 /

+1.52 (+5.12%)

KDP Keurig Dr Pepper
$36.85 /

-0.04 (-0.11%)

HQY HealthEquity
$82.31 /

+1.16 (+1.43%)

ETSY Etsy
$168.33 /

+4.13 (+2.52%)

CYCN Cyclerion Therapeutics
$3.13 /

-0.06 (-1.88%)

COUP Coupa Software
$236.34 /

+6.33 (+2.75%)

CHS Chico's
$5.75 /

+0.37 (+6.88%)

APR Apria
$31.01 /

+0.235 (+0.76%)

SFIX Stitch Fix
$58.21 /

+2.74 (+4.94%)

06/08/21 MKM Partners
Stitch Fix price target raised to $45 from $29 at MKM Partners
06/08/21 Wells Fargo
Stitch Fix price target raised to $35 from $27 at Wells Fargo
06/08/21 Morgan Stanley
Stitch Fix report had 'something for bulls and bears,' says Morgan Stanley
06/08/21 Baird
Stitch Fix price target raised to $70 from $60 at Baird
REVG REV Group
$19.63 /

+0.345 (+1.79%)

06/08/21 Baird
REV Group demand and operating momentum still building, says Baird
03/12/21 BMO Capital
REV Group price target raised to $19 from $10 at BMO Capital
03/11/21 Morgan Stanley
REV Group price target raised to $18 from $10 at Morgan Stanley
03/10/21 Baird
REV Group price target raised to $22 from $20 at Baird
MRVL Marvell
$48.30 /

-0.42 (-0.86%)

06/08/21 Craig-Hallum
Marvell price target raised to $63 from $52 at Craig-Hallum
06/08/21 Rosenblatt
Marvell price target raised to $70 from $60 at Rosenblatt
06/08/21 KeyBanc
Marvell price target raised to $60 from $55 at KeyBanc
06/08/21 Evercore ISI
Marvell price target raised to $63 from $55 at Evercore ISI
CYCN Cyclerion Therapeutics
$3.13 /

-0.06 (-1.88%)

SLQT SelectQuote
$19.55 /

-0.24 (-1.21%)

05/21/21 Piper Sandler
SelectQuote recent weakness a buying opportunity, says Piper Sandler
05/13/21 Truist
GoHealth price target lowered to $20 from $26 at Truist
05/12/21 Piper Sandler
SelectQuote should be bought on any guidance selloff, says Piper Sandler
04/06/21 Piper Sandler
SelectQuote assumed with an Overweight at Piper Sandler
CHS Chico's
$5.75 /

+0.37 (+6.88%)

03/03/21 B. Riley
Chico's price target raised to $2.50 from $2 at B. Riley Securities
01/15/21 B. Riley
Chico's price target raised to $2 from $1.50 at B. Riley Securities
11/17/20 B. Riley
Chico's downgraded to Neutral on delayed recovery at B. Riley Securities
11/17/20 B. Riley
Chico's downgraded to Neutral from Buy at B. Riley Securities
COUP Coupa Software
$236.34 /

+6.33 (+2.75%)

06/08/21 Needham
Coupa Software price target lowered to $280 from $385 at Needham
06/08/21 Truist
Coupa Software price target lowered to $326 from $386 at Truist
06/08/21 KeyBanc
Coupa Software price target lowered to $350 from $400 at KeyBanc
06/08/21 Raymond James
Coupa Software price target lowered to $300 from $365 at Raymond James
HQY HealthEquity
$82.31 /

+1.16 (+1.43%)

06/08/21 Cantor Fitzgerald
HealthEquity price target raised to $85 from $82 at Cantor Fitzgerald
04/29/21 JPMorgan
HealthEquity resumed with an Overweight at JPMorgan
03/22/21 Raymond James
HealthEquity price target lowered to $85 from $100 at Raymond James
03/17/21 Deutsche Bank
HealthEquity price target raised to $92 from $88 at Deutsche Bank
PLBY PLBY Group
$52.23 /

+6.38 (+13.91%)

05/13/21 Craig-Hallum
PLBY Group price target raised to $50 from $35 at Craig-Hallum
05/13/21 Canaccord
PLBY Group price target raised to $52 from $28 at Canaccord
04/07/21 Roth Capital
PLBY Group price target raised to $35 from $26 at Roth Capital
04/06/21 Canaccord
Canaccord sees Nifty Gateway partnership as initial step in PLBY's NFT strategy
APR Apria
$31.01 /

+0.235 (+0.76%)

05/17/21 Citi
Apria resumed with a Buy at Citi
04/15/21 Piper Sandler
Apria price target raised to $33 from $29 at Piper Sandler
03/31/21 Citi
Apria price target raised to $30 from $26 at Citi
03/31/21 Piper Sandler
Apria price target raised to $29 from $27 at Piper Sandler
LESL Leslie's
$31.22 /

+1.52 (+5.12%)

06/04/21 Loop Capital
Pool Corp. price target raised to $470 from $440 at Loop Capital
06/04/21 Loop Capital
Leslie's price target raised to $33 from $31 at Loop Capital
05/06/21 Loop Capital
Leslie's price target raised to $31 from $28 at Loop Capital
05/06/21 Baird
Leslie's price target raised to $35 from $33 at Baird
MARA Marathon Digital
$24.36 /

+0.03 (+0.12%)

05/26/21
Fly Intel: Top five analyst initiations
05/26/21 B. Riley
Marathon Digital initiated with a Buy, $47 target at B. Riley
05/25/21 B. Riley
Marathon Digital initiated with a Buy at B. Riley
03/17/21 H.C. Wainwright
Marathon Digital price target raised to $50 from $30 at H.C. Wainwright
KDP Keurig Dr Pepper
$36.85 /

-0.04 (-0.11%)

03/19/21
Fly Intel: Top five analyst upgrades
03/19/21 JPMorgan
Keurig Dr Pepper upgraded to Overweight from Neutral at JPMorgan
03/11/21 Morgan Stanley
Morgan Stanley downgrades Keurig Dr Pepper to Equal Weight after outperformance
03/11/21 Morgan Stanley
Keurig Dr Pepper downgraded to Equal Weight from Overweight at Morgan Stanley
RIOT Riot Blockchain
$28.82 /

-0.33 (-1.13%)

06/01/21 B. Riley
Riot Blockchain deal closing 'major positive' for shares, says B. Riley
06/01/21 H.C. Wainwright
Riot Blockchain price target raised to $40 from $30 at H.C. Wainwright
05/26/21 B. Riley
Riot Blockchain initiated with a Buy, $43 target at B. Riley
ETSY Etsy
$168.33 /

+4.13 (+2.52%)

06/07/21
Fly Intel: Top five analyst initiations
06/07/21 Atlantic Equities
Etsy initiated with an Overweight, $200 target at Atlantic Equities
06/07/21 Atlantic Equities
Etsy initiated with an Overweight at Atlantic Equities
06/03/21 Roth Capital
Depop acquisition deepens Etsy apparel/youth cohort expansion, says Roth Capital
SLQT SelectQuote
$19.55 /

-0.24 (-1.21%)

SFIX Stitch Fix
$58.21 /

+2.74 (+4.94%)

RIOT Riot Blockchain
$28.82 /

-0.33 (-1.13%)

REVG REV Group
$19.63 /

+0.345 (+1.79%)

PLBY PLBY Group
$52.23 /

+6.38 (+13.91%)

MRVL Marvell
$48.30 /

-0.42 (-0.86%)

MARA Marathon Digital
$24.36 /

+0.03 (+0.12%)

LESL Leslie's
$31.22 /

+1.52 (+5.12%)

KDP Keurig Dr Pepper
$36.85 /

-0.04 (-0.11%)

HQY HealthEquity
$82.31 /

+1.16 (+1.43%)

ETSY Etsy
$168.33 /

+4.13 (+2.52%)

COUP Coupa Software
$236.34 /

+6.33 (+2.75%)

CHS Chico's
$5.75 /

+0.37 (+6.88%)

APR Apria
$31.01 /

+0.235 (+0.76%)

  • 10
    Jun
  • 10
    Jun
  • 08
    Jun
  • 10
    Jun
  • 17
    Mar
  • 04
    Mar
  • 17
    Feb
  • 11
    Feb
  • 11
    Feb
  • 17
    Nov
  • 03
    Nov
  • 29
    Oct
  • 18
    Aug
  • 03
    Aug
  • 24
    Jul
  • 09
    Jul
SFIX Stitch Fix
$58.21 /

+2.74 (+4.94%)

RIOT Riot Blockchain
$28.82 /

-0.33 (-1.13%)

PLBY PLBY Group
$52.23 /

+6.38 (+13.91%)

MRVL Marvell
$48.30 /

-0.42 (-0.86%)

ETSY Etsy
$168.33 /

+4.13 (+2.52%)

SLQT SelectQuote
$19.55 /

-0.24 (-1.21%)

SFIX Stitch Fix
$58.21 /

+2.74 (+4.94%)

RIOT Riot Blockchain
$28.82 /

-0.33 (-1.13%)

REVG REV Group
$19.63 /

+0.345 (+1.79%)

PLBY PLBY Group
$52.23 /

+6.38 (+13.91%)

MRVL Marvell
$48.30 /

-0.42 (-0.86%)

MARA Marathon Digital
$24.36 /

+0.03 (+0.12%)

LESL Leslie's
$31.22 /

+1.52 (+5.12%)

KDP Keurig Dr Pepper
$36.85 /

-0.04 (-0.11%)

HQY HealthEquity
$82.31 /

+1.16 (+1.43%)

ETSY Etsy
$168.33 /

+4.13 (+2.52%)

COUP Coupa Software
$236.34 /

+6.33 (+2.75%)

APR Apria
$31.01 /

+0.235 (+0.76%)

SLQT SelectQuote
$19.55 /

-0.24 (-1.21%)

SFIX Stitch Fix
$58.21 /

+2.74 (+4.94%)

RIOT Riot Blockchain
$28.82 /

-0.33 (-1.13%)

PLBY PLBY Group
$52.23 /

+6.38 (+13.91%)

MRVL Marvell
$48.30 /

-0.42 (-0.86%)

MARA Marathon Digital
$24.36 /

+0.03 (+0.12%)

LESL Leslie's
$31.22 /

+1.52 (+5.12%)

ETSY Etsy
$168.33 /

+4.13 (+2.52%)

COUP Coupa Software
$236.34 /

+6.33 (+2.75%)

Hot Stocks
Cyclerion Therapeutics CEO buys 302K shares of common stock » 17:29
06/07/21
06/07
17:29
06/07/21
17:29
CYCN

Cyclerion Therapeutics

$3.13 /

-0.06 (-1.88%)

In a regulatory filing,…

In a regulatory filing, Cyclerion Therapeutics disclosed that its CEO Peter Hecht bought 823K shares of common stock on June 3rd in a total transaction size of $2.7M, boosting his stake by about 67%. Shares of Cyclerion Therapeutics are up over 4% at $3.28 after-hours following the disclosed transaction.

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.13 /

-0.06 (-1.88%)

Hot Stocks
Cyclerion Therapeutics announces $18M private placement » 08:21
06/04/21
06/04
08:21
06/04/21
08:21
CYCN

Cyclerion Therapeutics

$3.24 /

+ (+0.00%)

Cyclerion Therapeutics…

Cyclerion Therapeutics announced a direct private sale of approximately $18M of Cyclerion shares of common stock to EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners, LP, Invus, Peter Hecht, Ph.D., Lincoln Park Capital Fund, LLC and Polaris Partners. In the private placement, signed on June 3, 2021, the Company agreed to sell 5,735,988 shares of common stock at a price of $3.12 per share, or $3.28 per share with respect to Peter Hecht, Ph.D. in compliance with Nasdaq listing rules.

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.24 /

+ (+0.00%)

Hot Stocks
Cyclerion Therapeutics announces licensing agreement with Akebia Therapeutics » 08:15
06/04/21
06/04
08:15
06/04/21
08:15
CYCN

Cyclerion Therapeutics

$3.24 /

+ (+0.00%)

, AKBA

Akebia

$3.32 /

-0.045 (-1.34%)

Cyclerion Therapeutics…

Cyclerion Therapeutics (CYCN) announced that it has entered into an exclusive, global license agreement with Akebia Therapeutics (AKBA) for the development and commercialization of praliciguat, an oral sGC stimulator. Under the terms of the agreement, Akebia has obtained an exclusive license to research, develop and commercialize praliciguat globally and will be solely responsible for these activities going forward. Cyclerion is eligible to receive up to $225M in pre-commercial milestones, including up to $15M in the first 18 months. Total potential future development, regulatory, and commercialization milestone payments could result in up to $585M. Cyclerion is also eligible to receive tiered, sales-based royalties ranging from single-digit to high-teen percentages. "We are very pleased to license praliciguat to Akebia, whose demonstrated leadership in kidney disease and extensive R&D and commercialization capabilities make it an ideal partner for the future development of praliciguat. This transaction provides Cyclerion with meaningful participation in any potential near and longer-term value creation and enables us to focus on our mission to develop treatments for cognitive impairment, including our foundational assets CY6463 and CY3018, where we see enormous clinical promise," said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion.

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.24 /

+ (+0.00%)

AKBA Akebia
$3.32 /

-0.045 (-1.34%)

CYCN Cyclerion Therapeutics
$3.24 /

+ (+0.00%)

AKBA Akebia
$3.32 /

-0.045 (-1.34%)

06/01/21 H.C. Wainwright
Akebia NDA accepted with no FDA panel planned, says H.C. Wainwright
06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
04/07/21 Piper Sandler
Piper 'incrementally positive' on Akebia after 'surprising' FibroGen update
03/30/21 Piper Sandler
Piper likes setup for Akebia shares after vadadustat submission
AKBA Akebia
$3.32 /

-0.045 (-1.34%)

AKBA Akebia
$3.32 /

-0.045 (-1.34%)

AKBA Akebia
$3.32 /

-0.045 (-1.34%)

Syndicate
Cyclerion Therapeutics announces $18M private placement » 08:01
06/04/21
06/04
08:01
06/04/21
08:01
CYCN

Cyclerion Therapeutics

$3.24 /

+ (+0.00%)

Cyclerion Therapeutics…

Cyclerion Therapeutics announced a direct private sale of approximately $18M of Cyclerion shares of common stock to EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners, LP, Invus, Peter Hecht, Ph.D., Lincoln Park Capital Fund, LLC and Polaris Partners.

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.24 /

+ (+0.00%)

Over a quarter ago
Hot Stocks
Cyclerion Therapeutics announces highlights from webinar on CY6463 » 09:09
04/27/21
04/27
09:09
04/27/21
09:09
CYCN

Cyclerion Therapeutics

$3.13 /

+0.22 (+7.56%)

Cyclerion Therapeutics…

Cyclerion Therapeutics hosted a webinar to provide clinical updates for its first-in-class, CNS-penetrant soluble guanylate cyclase stimulator CY6463 in Alzheimer's Disease with Vascular pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes. Supported by recent clinical and preclinical data, Cyclerion also discussed the potential for CY6463 to treat Cognitive Impairment Associated with Schizophrenia, with key insights from Dr. Andreas Reif on the role of the sGC pathway in the disease. In addition, Cyclerion introduced its latest development candidate CY3018, a differentiated, next-generation, CNS-penetrant sGC stimulator. Modulating a fundamental CNS signaling pathway: sGC stimulators amplify the power of the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate pathway signaling to address central aspects of disease pathophysiology. Preclinical data from CY6463 and extensive academic work validate the crucial role of the sGC pathway in brain physiology. Clinical data from the recent translational pharmacology study confirm the ability of CY6463 to impact brain oscillations, neuroinflammation and neurophysiological function. CY6463 Updates: Disease-relevant, biomarker-guided pipeline strategy: The company is advancing parallel, signal-seeking, exploratory studies in well-defined patient populations with cognitive impairment including neurodegenerative, neuropsychiatric, and mitochondrial diseases. CY6463 targets sGC, a proven druggable target, in critical brain regions and cell types linked to cognition and has demonstrated an impact on multiple biomarkers associated with cognition in previous Phase 1 studies. ADv clinical trial initiation: The U.S. Food and Drug Administration cleared the Investigational New Drug (IND) application for CY6463 in ADv, and the Company anticipates beginning to enroll patients in a 12-week Phase 2a clinical trial in patients with ADv by mid-2021, barring any COVID-19 related delays. This exploratory study is designed to evaluate safety, tolerability, and pharmacodynamic effects including impact on disease-relevant biomarkers. MELAS clinical trial advancement: This study is enrolling more slowly than initially projected, primarily due to COVID-19. Data from the exploratory 29-day open-label Phase 2a pilot study in patients with MELAS are now expected by year end 2021. Potential to treat CIAS with novel mechanism: Neuropsychiatric key opinion leader and expert in the neurobiology of nitric oxide and its relation to psychiatric disorders, Andreas Reif, M.D., Chair, Department of Psychiatry, University Hospital Frankfurt, discussed the sGC pathway and its role in cognitive function and CIAS. Reduced NO-sGC-cGMP signaling is linked to cognitive dysfunction in schizophrenia. Stimulation of sGC by CY6463 to amplify NO-sGC-cGMP signaling is a potential first-in-class approach for the treatment of CIAS. Cyclerion is planning to initiate a Phase 1b signal-seeking study in CIAS to evaluate safety and near-term impact on disease-relevant biomarkers. CY3018, a differentiated, next-generation CNS-penetrant sGC stimulator: Cyclerion shared information on the latest development candidate, CY3018. Preclinical data show increased CNS-exposure, with significantly increased cerebrospinal fluid to plasma ratio, compared to CY6463. This increased CNS distribution is mirrored by a higher level of pharmacological activity in the CNS relative to the periphery. The company is advancing CY3018 through IND-enabling development. Cash, cash equivalents, and restricted cash balance on March 31, 2021 was approximately $45 million, as compared to approximately $58 million on December 31, 2021. As of April 2021, Cyclerion has substantially streamlined its operating model to invest more fully in its priority opportunities in cognition and expects average monthly cash use for the foreseeable future to be approximately 50 percent that of 2020.

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.13 /

+0.22 (+7.56%)

CYCN Cyclerion Therapeutics
$3.13 /

+0.22 (+7.56%)

Conference/Events
Cyclerion Therapeutics to hold a virtual corporate update » 07:55
04/27/21
04/27
07:55
04/27/21
07:55
CYCN

Cyclerion Therapeutics

$3.13 /

+0.22 (+7.56%)

Management holds a…

Management holds a corporate update on the Company's pipeline of novel candidates aimed at restoring cognitive function on April 27 at 8 am. Webcast Link

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.13 /

+0.22 (+7.56%)

CYCN Cyclerion Therapeutics
$3.13 /

+0.22 (+7.56%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.